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Abstract  A  case  is  reported  in  which  a  3-days  old  neonate  with  a  giant  ovarian  cyst  was  sched-
uled for  surgery.  The  patient  received  a  dose  of  sugammadex  to  reverse  a  rocuronium-induced
neuromuscular  block.  A  fast  and  efﬁcient  recovery  from  neuromuscular  block  was  achieved
within 90  s.  No  adverse  events  or  other  safety  concerns  were  observed.  Furthermore,  a  review
of the  literature  on  the  use  of  sugammadex  in  neonates  was  performed.
© 2015  Sociedade  Brasileira  de  Anestesiologia.  Published  by  Elsevier  Editora  Ltda.  This
is an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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Rocurônio  e  sugamadex  em  recém-nascido  de  3  dias  para  drenagem  de  um  cisto
ovariano.  Controle  neuromuscular  e  revisão  da  literatura
Resumo  Relato  do  caso  de  uma  crianc¸a  recém-nascida  de  3  dias  de  idade  com  um  cisto  ovar-
iano gigante  programada  para  a  cirurgia.  A  paciente  recebeu  uma  dose  de  sugamadex  para
reverter o  bloqueio  neuromuscular  induzido  por  rocurônio.  Uma  recuperac¸ão  rápida  e  eﬁciente
do bloqueio  neuromuscular  foi  obtida  dentro  de  90  segundos.  Não  foram  observados  efeitos
adversos ou  outros  problemas  de  seguranc¸a.  Além  disso,  uma  revisão  da  literatura  sobre  o  uso
de sugamadex  em  recém-nascidos  foi  realizada.
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Introduction
Neonatal  ovarian  cysts  are  uncommon.  The  incidence  of
these  cysts  is  1/2500  live  birth  and  are  often  detected  during
antenatal  echography  in  the  late  pregnancy.1--3 These  cysts
are  associated  with  prenatal  and  postnatal  complications
like  ovarian  torsion  which  could  lead  to  ovarian  loss,  espe-
cially  in  voluminous  cysts.1 Therefore,  the  management  of
these  ovarian  cysts  include  observation  and  surgical  inter-
vention  when  symptomatic.1,2
Rocuronium  is  a  commonly  used  neuromuscular  block-
ing  agent  (NMBA)  in  clinical  anesthesia  and  administered
in  all  age  groups,  including  neonates.  Sugammadex  is  the
ﬁrst  selective  relaxant  binding  agent  designed  to  reverse
a  neuromuscular  block  (NMB)  induced  by  either  rocuro-
nium  or  vecuronium.  Sugammadex  has  been  investigated  in
adults  and  children  older  than  4  years  of  age,  but  there
is  limited  data  available  about  the  efﬁcacy  and  safety
of  sugammadex  reversal  of  a  rocuronium-induced  NMB  in
neonates.3,4
We  report  a  case  in  which  a  3  days  old  neonate  with  a
giant  ovarian  cyst  received  a  dose  of  sugammadex  to  reverse
a  rocuronium-induced  deep  NMB.  The  safety  and  efﬁcacy  of
sugammadex  are  discussed.  Furthermore,  a  review  of  the
literature  on  the  use  of  sugammadex  in  neonates  was  per-
formed.
Case report
A  3  days-old  female  neonate  (weight  2.98  kg)  presented  with
a  giant  ovarian  cyst  with  a  volume  of  180  mL  conﬁrmed  by
ultrasonography.  Physical  examination  revealed  a  palpable
mass  in  the  abdominal  region.  Further  examination  showed
no  other  pathology.  After  obtaining  informed  consent  from
the  mother,  the  neonate  was  scheduled  for  open  surgery  to
drain  the  cyst  under  general  anesthesia.
An  intravenous  (IV)  line  was  inserted  previously.  Standard
intraoperative  monitoring  included  ECG,  NIBP,  pulse  oxime-
try,  capnography,  anesthetic  gas  analyzer  and  esophageal
thermometer.  The  neuromuscular  function  was  monitored
using  train-of-four  (TOF)  stimulation  of  the  ulnar  nerve  and
was  quantitated  with  acceleromyography  (TOF-WatchTM SX,
Schering-Plough  Ireland  Ltd.,  Dublin,  Ireland).  The  primary
efﬁcacy  variable  for  reversal  was  deﬁned  as  the  time  from
the  start  of  the  administration  of  sugammadex,  to  recovery
of  the  TOF-ratio  to  0.9.
After  preoxygenation,  anesthesia  was  induced  with
sevoﬂurane  through  facial  mask  and  intravenous  opioid.
Procedures  for  the  set-up,  calibration  and  stabilization  of
neuromuscular  monitoring  were  executed.  The  patient  then
received  an  IV  bolus  injection  of  rocuronium  0.9  mg  kg−1.
This  was  followed  by  endotracheal  intubation,  and  the  lungs
were  ventilated  with  a  mixture  of  oxygen  and  air  in  a
ratio  of  2:3.  The  surgical  procedure  was  uneventful,  240  mL
of  ﬂuid  was  drained  from  the  ovarian  cyst  and  a  partial
oophorectomy  was  performed.  The  duration  of  anesthesia
was  75  min.  At  the  end  of  the  procedure  neuromuscular
monitoring  showed  one  post-tetanic  count  (PTC  1),  indicat-
ing  a  deep  NMB.  Reversal  of  rocuronium-induced  NMB  was
performed  by  administration  of  4.0  mg  kg−1 sugammadex
(12  mg).  The  time  to  recovery  from  rocuronium-induced
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MB  to  a  TOF-ratio  of  0.9  was  90  s.  No  changes  from  base-
ine  were  observed  in  blood  pressure  or  heart  rate  after
dministration  of  the  sugammadex  dose.  Eighth  minutes
fter  the  administration  of  sugammadex  the  trachea  was
xtubated  and  the  patient  was  discharged  to  the  neonatal
are.  The  patient’s  recovery  from  anesthesia  was  unevent-
ul  and  no  signs  of  residual  NMB  or  recurarization  were
bserved.
eview  of  the  literature
he  review  of  the  literature  was  performed  in  PubMed  and  in
ersonal  archives  of  both  authors  with  search  criteria  sug-
mmadex  and  neonates.  Inclusion  criteria  were:  neonates
reated  with  sugammadex,  articles  in  English  language.
hese  publications  were  collected  and  analyzed.  The  lit-
rature  search  on  sugammadex  and  neonates  showed  only
wo  publications  which  met  the  inclusion  criteria  (none  in
ubmed)  in  which  24  patients  were  described  and  will  be
iscussed  in  Section  ‘‘Discussion’’.4,5
iscussion
he  reversal  of  a  rocuronium-induced  profound  NMB  with
ugammadex  4.0  mg  kg−1 in  our  patient  was  fast,  complete
nd  without  signs  of  postoperative  residual  curarization
PORC)  or  recurarization.  Sugammadex  was  safe  and  well
olerated.  Reversal  of  NMB  is  important  for  the  accelera-
ion  of  the  patient’s  recovery  and  the  prevention  of  PORC.
ocuronium-induced  NMB  can  be  reversed  by  cholinesterase
nhibitors.  However,  reversal  of  NMB  with  cholinesterase
nhibitors  (in  combination  with  muscarinic  antagonists)  has
imitations  due  to  its  mechanism  of  action  (ineffective
gainst  profound  NMB)  and  is  often  associated  with  unde-
irable  cholinergic  side-effects.
Sugammadex  is  able  to  bind  the  steroidal  NMB  drug
ocuronium  or  vecuronium,  forming  a  complex.  Encapsula-
ion  of  the  rocuronium  molecule  by  sugammadex  results  in
 rapid  decrease  in  free  rocuronium  in  the  plasma  and  sub-
equently  at  the  nicotinic  receptor  at  the  motor  endplate,
eading  to  a  rapid  reappearance  of  muscle  activity.  After
ncapsulation,  rocuronium  is  not  available  to  bind  to  the
icotinic  receptor  in  the  neuromuscular  junction.  This  pro-
otes  the  liberation  of  acetylcholine  receptors,  and  muscle
ctivity  reappears.
iscussion  of  the  review  of  the  literature
n  two  publications  24  neonatal  cases  in  which  sugammadex
as  administered  were  described.4,5 In  one  publication  a
0  day-old  patient  (weight  2.6  kg)  received  12  mg  sugam-
adex  to  reverse  a  rocuronium-induced  deep  neuromuscular
lock.  Within  2  min  the  TOF-ratio  recovered  >0.9.  No  con-
erns  about  safety  related  to  sugammadex  were  reported.5
n  the  other  publication  23  patients  were  reported  who  were
ivided  into  two  groups:  A,  1  day  old  (n  =  8,  mean  weight  [kg
nd  SD]  2.8  [0.8])  and  B,  1--7  days  old  (n  =  15,  mean  weight
kg  and  SD]  2.4  [0.8]).4 All  neonates  received  sugammadex
.0  mg  kg−1 for  reversal  of  a  rocuronium-induced  deep  NMB.
he  recovery  to  a  TOF-ratio  was  in  group  A  1.4  (0.9)  (min
nd  SD)  and  1.2  (0.5)  respectively.  Sugammadex  was  safe
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432  
nd  well  tolerated.  In  all  patients  the  recovery  was  fast  and
omplete.
The  results  of  our  patient  were  in  line  with  the  results
ound  in  the  literature  and  doses  of  sugammadex  4.0  mg  kg−1
roduced  similar  recovery  times  as  in  other  age  groups.3
herefore  dosing  and  recovery  times  are  identical  in  all  age
roups  and  the  use  of  sugammadex  in  neonates  may  be  also
omparable  beneﬁcial  as  shown  in  other  patients  age  groups.
his  has  to  be  conﬁrmed  in  more  cases  or  dedicated  stud-
es.  Furthermore,  neuromuscular  management  in  neonates
hould  also  consist  of  the  choice  of  an  appropriate  NMBA,
bjective  neuromuscular  monitoring  and  adequate  reversal
o  prevent  PORC.isclosure
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